Table 3.
Crude and adjusted median difference and odds ratios (ORs) for different outcomes during COVID-19 hospitalisations from March 1 to October 31, 2020, with corresponding 95% confidence intervals (CI), for patients with IBD, relative to patients without any of these prior diseases.
| Outcome |
Exposed IBD patients N = 52 Median (p25-p75) |
Unexposed patients N = 2811 Median (p25-p75) |
Difference |
P-value |
Adjusted Differencea |
95% CI |
Adjusted Differenceb |
95% CI |
|---|---|---|---|---|---|---|---|---|
| Hospital stay duration |
6.8 (2.3–13.6) |
5.5 (2.6–9.9) |
1.3 |
0.24 |
0.40 |
(-1.47-2.27) |
0.43 |
(-1.48-2.35) |
| Events (%) | Events (%) | Crude OR | 95% CI | Adjusted ORa | 95% CI | Adjusted ORb | 95% CI | |
| Ventilator | 4 (7.7) | 265 (9.4) | 0.80 | (0.29–2.24) | 0.67 | (0.23–1.91) | 0.66 | (0.23–1.94) |
| CPAP | 5 (9.6) | 247 (8.8) | 1.10 | (0.44-2.80) | 0.91 | (0.35–2.33) | 0.90 | (0.35–2.33) |
| In-hospital death | 8 (15.4) | 426 (15.2) | 1.02 | (0.48–2.18) | 0.76 | (0.34–1.69) | 0.68 | (0.30–1.53) |
| Death 14 days | 10 (19.2) | 508 (18.1) | 1.08 | (0.54-2.17) | 0.82 | (0.39–1.72) | 0.74 | (0.35–1.58) |
| Death 30 days | 11 (21.2) | 537 (19.1) | 1.14 | (0.58–2.23) | 0.85 | (0.41–1.77) | 0.79 | (0.38–1.64) |
Adjustment for: a) gender, age, and Charlson's comorbidity index, b) medication categories (Thiopurines, Methotrexate, Systemic corticosteroids, anti-TNFalfa agents), gender, age, and Charlson's comorbidity index.